Biogen To Present New Data Across Alzheimer’s Disease Portfolio At AAIC 2026, Presentations To Include Data From Phase 2 CELIA Study Evaluating Diranersen, And New Analyses From Studies Of LEQEMBI

Loading news article.

Biogen To Present New Data Across Alzheimer’s Disease Portfolio At AAIC 2026, Presentations To Include Data From Phase 2 CELIA Study Evaluating Diranersen, And New Analyses From Studies Of LEQEMBI | WAPE

Biogen To Present New Data Across Alzheimer’s Disease Portfolio At AAIC 2026, Presentations To Include Data From Phase 2 CELIA Study Evaluating Diranersen, And New Analyses From Studies Of LEQEMBI

Article summary

Related companies

Comments —